Detail page

Media

Mathias Witzens-Harig, Marie-Luise Memmer, Martin Dreyling et al.

A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial

Published in: BMC cancer 13, 1, 25.6.2013, date:12.2013

Title	A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial
Involved	Mathias Witzens-Harig (Verfasser) Marie-Luise Memmer (Mitwirkender) Martin Dreyling (Mitwirkender) Georg Hess (Mitwirkender) SpringerLink (Online service) (Herausgebendes Organ)
Published in	BMC cancer 13, 1, 25.6.2013, date:12.2013, Seite 1-5
Published	2013
Language	Englisch
Country	Großbritannien
Subject	Biomedicine. Cancer Research. Oncology.
Persistent identifier	urn:nbn:de:1111-201603049156 (URN) 10.1186/1471-2407-13-308 (DOI)
Record ID	1085631729

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial